

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person * <u>Foley Todd</u> (Last) (First) (Middle) <u>C/O MPM ASSET MANAGEMENT</u> <u>200 CLARENDON STREET, 54TH FLOOR</u> (Street) <u>BOSTON MA 02116</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>01/29/2014</u>	3. Issuer Name and Ticker or Trading Symbol <u>Celladon Corp [CLDN]</u>	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	--	--	---	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A-1 Preferred Stock	(1)	(1)	Common Stock	943,797	(1)	I	See Footnote ⁽²⁾
Warrants to Purchase Series A-1 Preferred Stock-Right to Buy	10/15/2013	10/15/2018	Series A-1 Preferred Stock	218,806	0.449	I	See Footnote ⁽³⁾
Convertible Promissory Notes	(4)	(4)	Common Stock	\$89,313.48	(4)	I	See Footnote ⁽⁵⁾
Stock Option (Right to Buy)	(6)	01/28/2024	Common Stock	20,000	8	D	

Explanation of Responses:

1. Each share of Series A-1 Preferred Stock is convertible into 0.080064 of Common Stock without payment of further consideration and will automatically convert into 0.080064 of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
2. The shares (on an as-converted to Common Stock basis) are held as follows: 884,566 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 34,078 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 25,153 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. Todd Foley is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
3. The warrants are held as follows: 205,075 by BV IV QP, 7,900 by BV IV KG and 5,831 by AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
4. Consists of principal, that together with accrued interest, will convert immediately prior to the closing of the Issuer's initial public offering into shares of Common Stock at a conversion price equal to the public offering price of the Common Stock sold in the Issuer's initial public offering.
5. The principal amount of the notes are held as follows: \$83,708.25 by BV IV QP, \$3,224.93 by BV IV KG and \$2,380.30 by AM BV4.
6. The shares vest 1/36th per month beginning one month after January 29, 2014 (the "Vesting Commencement Date") and continue thereafter until the option shall be fully vested and exercisable on the three year anniversary of the Vesting Commencement Date.

Remarks:

Todd Foley 01/29/2014
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.